The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam Hai-Binh Bui, Hong-Thinh Lai, Thanh-Lam Nguyen, Thuy-Duong Vu, Nhat-Le Bui, Van-Hung Nguyen, Thi-To-Chau Tran, Thi-Phuong-Thuy Nguyen, Thi-Ngoc-Lan Nguyen, Jaffar A. Al-Tawfiq, Dinh-Toi Chu

Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis Jesús Tornero-Molina, Mercedes Alperi-López, Ivan Castellví, Juan José de Agustín-de Oro, Alejandro Escudero, Rosario García-Vicuña, Miguel Ángel González-Gay, Cristina Hidalgo, Esteban Rubio, Raimon Sanmartí, Núria Casamira, Jaime Calvo-Alén

Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study Pilar Espiño-Lorenzo, Sara Manrique-Arija, Inmaculada Ureña, Francisco Gabriel Jiménez-Núñez, María López-Lasanta, Carmen María Romero-Barco, María Angeles Belmonte-López, María Victoria Irigoyen, Antonio Fernández-Nebro